Table 1 Summary of tumor-related peptide drugs ranked in the global top 25 sales of peptide drugs in 2022
From: Exploring treatment options in cancer: tumor treatment strategies
Product Name | Company | Disease | Approval Date | 2022 sales revenue (in billions USD) |
|---|---|---|---|---|
Sandostatin | Novartis | Tumour | 1988 | 12.38 |
Zoladex | AstraZenca | Cancer | 1989 | 9.27 |
Decapeptyl | Ipsen | Hormone-dependent prostate cancer | 1986 | 5.57 |
Lutathera | Novartis | Gastrointestinal pancreatic neuroendocrine tumor | 2017 | 4.71 |
